ClinicalTrials.gg
CompletedNCT07342088Updated Jan 16, 2026

Lactobacillus Acidophilus and Limosilactobacillus Reuteri for Acute Diarrhea in Children

An interventional study of Probiotic and Standard therapy in Infectious Diarrhea and Acute Gastroenteritis, sponsored by Eskisehir Osmangazi University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 1 Year to 6 Years. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Eskisehir Osmangazi University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled May 2024, registered Jan 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
1 Year to 6 Years
Sex
All
01

Study summary

This randomized controlled trial evaluated the effect of a combination of Lactobacillus acidophilus DSMZ 26280 and Limosilactobacillus reuteri DSMZ 25441 on the duration of diarrhea and gut microbiota composition in children aged 1-6 years with acute infectious diarrhea.

Read the detailed description

This prospective, randomized, controlled, open-label clinical trial was conducted between March 2024 and August 2024 at the Pediatric Emergency Department of Prof. Dr. İlhan Varank Sancaktepe Training and Research Hospital, Istanbul, Türkiye. Children aged 1-6 years presenting within 24 hours of onset of acute infectious diarrhea were randomized 1:1 to receive standard therapy (oral rehydration solution with or without intravenous fluids) alone or in combination with a probiotic preparation containing Lactobacillus acidophilus DSMZ 26280 (1×10⁸ CFU) and Limosilactobacillus reuteri DSMZ 25441 (1×10⁸ CFU) administered once daily for 5 days.

The primary outcomes were duration of diarrhea and the proportion of children who were diarrhea-free at 72 hours. Secondary outcomes included the proportion of children with diarrhea during the first 10 days of follow-up. A subgroup underwent longitudinal gut microbiota analysis at baseline, day 10, and day 30 using 16S rRNA sequencing.

The study was approved by the Ethics Committee of Prof. Dr. İlhan Varank Sancaktepe Training and Research Hospital (approval date April 17, 2024; decision no: 126), and written informed consent was obtained from all parents or legal guardians.

02

Conditions studied

  • Infectious Diarrhea
  • Acute Gastroenteritis

Browse trials for

Keywords

  • probiotic
  • acute infectious diarrhea
  • children
  • microbiota
03

In context

Dysentery

44 studies on the registry are indexed under Dysentery; 6 are open to participants now.

This study's enrollment of 145 is below the median of 163 across 38 interventional studies indexed under Dysentery.

Browse Dysentery studies →

Lead sponsor

Eskisehir Osmangazi University is the lead sponsor of 153 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 1-6 years
  • Clinical diagnosis of acute infectious diarrhea
  • Presentation within 24 hours of symptom onset
  • Mild or no dehydration
  • Written from parents or guardians

Exclusion criteria

Exclusion Criteria:

  • Antibiotic or probiotic use within the previous month
  • Moderate or severe dehydration
  • Malnutrition
  • Chronic systemic disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Probiotic Group

    Probiotic combination of Lactobacillus acidophilus DSMZ 26280 (1×10⁸ CFU) and Limosilactobacillus reuteri DSMZ 25441 (1×10⁸ CFU), administered orally as drops once daily for 5 days, in addition to standard rehydration therapy.

    Dietary Supplement: Probiotic · Other: Standard therapy

  • Active comparator
    Control group

    Standard therapy consisting of oral rehydration solution with or without intravenous fluids.

    Other: Standard therapy

Interventions

  • Dietary supplementProbiotic

    A probiotic preparation containing Lactobacillus acidophilus DSMZ 26280 (1×10⁸ CFU) and Limosilactobacillus reuteri DSMZ 25441 (1×10⁸ CFU) administered orally as drops once daily for 5 consecutive days, in addition to standard rehydration therapy.

  • OtherStandard therapy

    Standard management of acute infectious diarrhea consisting of oral rehydration solution with or without intravenous fluids according to clinical need.

06

What researchers measure

Primary outcomes

  1. Duration of diarrhea

    Time from randomization to last diarrheal stool

    Time frame: Up to 10 days

  2. Proportion of children free of diarrhea at 72 hours

    Proportion of children free of diarrhea at 72 hours

    Time frame: 72 hours after start of treatment

Secondary outcomes

  1. Proportion of children with ongoing diarrhea

    Percentage of children with diarrhea recorded daily for the first 10 days.

    Time frame: Days 1-10

07

Study locations

1 site
  • Sancaktepe Ilhan Varank Research and Training Hospital, University of Health Sciences,
    Istanbul, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Aug 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 15, 2026
StartActual
May 1, 2024
Primary completionActual
Aug 31, 2024
CompletionActual
Apr 30, 2025
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07342088
Collaborators
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
Responsible party
Ener Cagri DINLEYICI (Prof.Dr, Eskisehir Osmangazi University) — Principal investigator
First posted
Jan 15, 2026
Start date
May 1, 2024
Primary completion
Aug 31, 2024
Completion
Apr 30, 2025
Last update
Jan 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion